Table 4A

Continued

CovariateCrude odds ratio95% confidence intervalPAdjusted odds ratioa95% confidence intervalP
IGF-I levels
 <97.41.001.00
 97.4–119.10.710.5–1.00.040.690.5–1.00.05
 119.2–150.20.710.5–1.00.040.730.5–1.10.09
 >150.20.690.5–0.90.030.670.5–0.90.04
IGFBP-3 levels
 >2636.61.001.00
 2308.8–2636.60.810.6–1.20.250.790.5–1.20.24
 1967.0–2308.71.140.8–1.60.461.020.7–1.50.91
 <1967.01.290.9–1.80.141.270.9–1.20.21
  • a Each genetic marker assumed to be independent. Thus, each genetic marker adjusted for age, PSA, free:total prostate-specific antigen (PSA) ratio, digital rectal exam (DRE), ethnicity, family history and obstructive voiding symptoms. IGF-1 and IGFBP-3 considered together in a multivariate model adjusting for age, PSA, free:total PSA ratio, DRE, ethnicity, family history and obstructive voiding symptoms.

  • b CAG repeat units also considered as continuous variable. Adjusted odds ratio = 1.01 for prostate cancer per CAG repeat unit increase (95% confidence interval, 0.97–1.05; P = 0.57).